

244 - References

References

Schizophrenia and related psychoses CHAPTER 1 References

1. Thompson A, et al. Late onset neutropenia with clozapine. *Can J Psychiatry* 2004; 49:647-648.
2. Bhanji NH, et al. Late-onset agranulocytosis in a patient with schizophrenia after 17 months of clozapine treatment. *J Clin Psychopharmacol* 2003; 23:522-523.
3. Sedky K, et al. Clozapine-induced agranulocytosis after 11 years of treatment [Letter]. *Am J Psychiatry* 2005; 162:814.
4. de Araujo CF, et al. Delayed-onset severe neutropenia associated with clozapine with successful rechallenge at lower dose. *J Clin Psychopharmacol* 2021; 41:77-79.
5. Kang BJ, et al. Long-term patient monitoring for clozapine-induced agranulocytosis and neutropenia in Korea: when is it safe to discontinue CPMS? *Hum Psychopharmacol* 2006; 21:387-391.
6. Panesar N, et al. Late onset neutropenia with clozapine. *Aust N Z J Psychiatry* 2011; 45:684.
7. Tourian L, et al. Late-onset agranulocytosis in a patient treated with clozapine and lamotrigine. *J Clin Psychopharmacol* 2011; 31:665-667.
8. Hawe R, et al. Response to clozapine-induced microscopic colitis: a case report and review of the literature. *J Clin Psychopharmacol* 2008; 28:454-455.
9. Shah V, et al. Clozapine-induced ischaemic colitis. *BMJ CaseRep* 2013; 2013:bcr2012007933.
10. Linsley KR, et al. Clozapine-associated colitis: case report and review of the literature. *J Clin Psychopharmacol* 2012; 32:564-566.
11. Baptista T. A fatal case of ischemic colitis during clozapine administration. *Rev Bras Psiquiatr* 2014; 36:358.
12. Rodriguez-Sosa JT, et al. Apropos of a case: relationship of ischemic colitis with clozapine. *Actas Esp Psiquiatr* 2014; 42:325-326.
13. Osterman MT, et al. Clozapine-induced acute gastrointestinal necrosis: a case report. *J Med Case Rep* 2017; 11:270.
14. Holz K, et al. Clozapine associated with microscopic colitis in the setting of biopsy-proven celiac disease. *J Clin Psychopharmacol* 2018; 38:150-152.
15. Rask SM, et al. Clozapine-related diarrhea and colitis: report of 4 cases. *J Clin Psychopharmacol* 2020; 40:293-296.
16. Verdoux H, et al. Clinical determinants of fever in clozapine users and implications for treatment management: a narrative review. *Schizophr Res* 2019; 211:1-9.

17. Peyriere H, et al. Antipsychotics-induced ischaemic colitis and gastrointestinal necrosis: a review of the French pharmacovigilance database. *Pharmacoepidemiol Drug Saf* 2009; 18:948-955.
18. Centorrino F, et al. Delirium during clozapine treatment: incidence and associated risk factors. *Pharmacopsychiatry* 2003; 36:156-160.
19. Shankar BR. Clozapine-induced delirium. *J Neuropsychiatry Clin Neurosci* 2008; 20:239-240.
20. Khanra S, et al. An unusual case of delirium after restarting clozapine. *Clin Psychopharmacol Neurosci* 2016; 14:107-108.
21. Gaertner HJ, et al. Side effects of clozapine. *Psychopharmacology (Berl)* 1989; 99 Suppl:S97-S100.
22. Friedrich ME, et al. Incidence of drug-induced delirium during treatment with antidepressants or antipsychotics: a drug surveillance report of German-speaking countries between 1993 and 2016. *Int J Neuropsychopharmacol* 2022; 25:556-566.
23. Hummer M, et al. Does eosinophilia predict clozapine induced neutropenia? *Psychopharmacology* 1996; 124:201-204.
24. Ames D, et al. Predictive value of eosinophilia for neutropenia during clozapine treatment. *J Clin Psychiatry* 1996; 57:579-581.
25. Wysokinski A, et al. Rapidly developing and self-limiting eosinophilia associated with clozapine. *Psychiatry Clin Neurosci* 2015; 69:122.
26. Aneja J, et al. Eosinophilia induced by clozapine: a report of two cases and review of the literature. *J Family Med Prim Care* 2015; 4:127-129.
27. Lally J, et al. Hepatitis, interstitial nephritis, and pancreatitis in association with clozapine treatment: a systematic review of case series and reports. *J Clin Psychopharmacol* 2018; 38:520-527.
28. Marchel D, et al. Multiorgan eosinophilic infiltration after initiation of clozapine therapy: a case report. *BMC Res Notes* 2017; 10:316.
29. Chatterton R. Eosinophilia after commencement of clozapine treatment. *Aust N Z J Psychiatry* 1997; 31:874-876.
30. Chan SY, et al. Clozapine-induced acute interstitial nephritis. *Hong Kong Med J* 2015; 21:372-374.
31. Lally J, et al. Rechallenge following clozapine-associated eosinophilia: a case report and literature review. *J Clin Psychopharmacol* 2019; 39:504-506.
32. Karmacharya R, et al. Clozapine-induced eosinophilic colitis [Letter]. *Am J Psychiatry* 2005; 162:1386-1387.
33. de Filippis R, et al. Antipsychotic-related DRESS syndrome: analysis of individual case safety reports of the WHO Pharmacovigilance Database. *Drug Saf* 2024; 47:745-757.
34. de Filippis R, et al. Unravelling cases of clozapine-related drug reaction with eosinophilia and systemic symptoms (DRESS) in patients reported otherwise: a systematic review. *J Psychopharmacol* 2021; 35:1062-1073.
35. McArdle PA, et al. Successful rechallenge with clozapine after treatment associated eosinophilia. *Australas Psychiatry* 2016; 24:365-367.
36. Fabrazzo M, et al. Clozapine versus other antipsychotics during the first 18 weeks of treatment: a retrospective study on risk factor increase of blood dyscrasias. *Psychiatry Res* 2017; 256:275-282.

37. Sanader B, et al. Clozapine-induced DRESS syndrome: a case series from the AMSP Multicenter Drug Safety Surveillance Project. *Pharmacopsychiatry* 2019; 52:156–159.
38. Kerwin RW, et al. Heat stroke in schizophrenia during clozapine treatment: rapid recognition and management. *J Psychopharmacol* 2004; 18:121–123.
39. Hoffmann MS, et al. Heat stroke during long-term clozapine treatment: should we be concerned about hot weather? *Trends Psychiatry Psychother* 2016; 38:56–59.
40. Erdogan A, et al. Management of marked liver enzyme increase during clozapine treatment: a case report and review of the literature. *Int J Psychiatry Med* 2004; 34:83–89.

248 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1

41. Macfarlane B, et al. Fatal acute fulminant liver failure due to clozapine: a case report and review of clozapine-induced hepatotoxicity. *Gastroenterology* 1997; 112:1707–1709.
42. Chang A, et al. Clozapine-induced fatal fulminant hepatic failure: a case report. *Can J Gastroenterol* 2009; 23:376–378.
43. Chaplin AC, et al. Re: Recent case report of clozapine-induced acute hepatic failure. *Can J Gastroenterol* 2010; 24:739–740.
44. Wu Chou AI, et al. Hepatotoxicity induced by clozapine: a case report and review of literature. *Neuropsychiatr Dis Treat* 2014; 10:1585–1587.
45. Kane JP, et al. Clozapine-induced liver injury and pleural effusion. *Ment Illn* 2014; 6:5403.
46. Douros A, et al. Drug-induced liver injury: results from the hospital-based Berlin Case–Control Surveillance Study. *Br J Clin Pharmacol* 2015; 79:988–999.
47. Tucker P. Liver toxicity with clozapine. *Aust N Z J Psychiatry* 2013; 47:975–976.
48. Fong SY, et al. Clozapine-induced toxic hepatitis with skin rash. *J Psychopharmacol* 2005; 19:107.
49. Burk BG, et al. A case report of acute hypothermia during initial inpatient clozapine titration with review of current literature on clozapine-induced temperature dysregulations. *BMC Psychiatry* 2020; 20:290.
50. McLoughlin C, et al. Clozapine-induced interstitial nephritis in a patient with schizoaffective disorder in the forensic setting: a case report and review of the literature. *Ir J Psychol Med* 2022; 39:106–111.
51. Vantipalli P, et al. Acute interstitial nephritis induced by clozapine. *J Med Cases* 2022; 13:322–329.
52. Can KC, et al. A very rare adverse effect of clozapine, clozapine-induced interstitial lung disease: case report and literature review. *Noro Psikiyatr Ars* 2019; 56:313–315.
53. Torrico T, et al. Clozapine-induced pneumonitis: a case report. *Front Psychiatry* 2020; 11:572102.
54. Sahib Din J, et al. Knee buckling as an atypical adverse effect of clozapine: a case report. *Cureus* 2024; 16:e55865.
55. Uzun Ö, et al. Knee buckling (negative myoclonus) associated with clozapine: reports on 3 cases. *Clin Neuropharmacol* 2020; 43:26–27.
56. Mu C, et al. Characteristics of eye disorders induced by atypical antipsychotics: a real-world study from 2016 to 2022 based on Food and Drug Administration Adverse Event Reporting System. *Front Psychiatry* 2024; 15:1322939.
57. Borovik AM, et al. Ocular pigmentation associated with clozapine. *Med J Aust* 2009; 190:210–211.
58. Huttlin EA, et al. Periorbital edema associated with clozapine and gabapentins: a case report. *J Clin Psychopharmacol* 2020; 40:198–199.
59. Ceylan E, et al. The ocular surface side effects of an anti-psychotic drug, clozapine. *Cutan Ocul Toxicol* 2016; 35:62–66.
60. Bergemann N, et al. Asymptomatic pancreatitis associated with clozapine. *Pharmacopsychiatry* 1999; 32:78–80.
61. Raja M, et al. A case of clozapine-associated pancreatitis. *Open Neuropsychopharmacol J* 2011; 4:5–7.
62. Bayard JM, et al. Case report: acute pancreatitis induced by Clozapine. *Acta Gastroenterol Belg* 2005; 68:92–94.
63. Sani G, et al. Development of asymptomatic pancreatitis with paradoxically high serum clozapine levels in a patient with schizophrenia and the CYP1A2*1F/1F genotype. *J Clin Psychopharmacol* 2010; 30:737–739.
64. Wehmeier PM, et al. Pancreatitis followed by pericardial effusion in an adolescent treated with clozapine. *J Clin Psychopharmacol* 2003; 23:102–103.
65. Garlipp P, et al. The development of a clinical syndrome of asymptomatic pancreatitis and eosinophilia after

treatment with clozapine in schizophrenia: implications for clinical care, recognition and management. *J Psychopharmacol* 2002; 16:399–400. 66. Gatto EM, et al. Clozapine and pancreatitis. *Clin Neuropharmacol* 1998; 21:203. 67. Martin A. Acute pancreatitis associated with clozapine use. *Am J Psychiatry* 1992; 149:714. 68. Yildiz MI, et al. All in one: clozapine-associated acute pancreatitis with multiple organ involvement. *J Clin Psychopharmacol* 2021; 41:214–216. 69. de Filippis R, et al. Clozapine-associated pericarditis and pancreatitis in children and adolescents: a systematic literature review and pharmacovigilance study using the VigiBase database. *Schizophr Res* 2024; 268:118–130. 70. Cerulli TR. Clozapine-associated pancreatitis. *Harv Rev Psychiatry* 1999; 7:61–63. 71. Huang YJ, et al. Recurrent pancreatitis without eosinophilia on clozapine rechallenge. *Prog Neuropsychopharmacol Biol Psychiatry* 2009; 33:1561–1562. 72. Chengappa KN, et al. Recurrent pancreatitis on clozapine re-challenge. *J Psychopharmacol* 1995; 9:381–382. 73. Frankenburg FR, et al. Eosinophilia, clozapine, and pancreatitis. *Lancet* 1992; 340:251. 74. Ratcliff K, et al. Clozapine rechallenge with recurrent pancreatitis. *Prim Care Companion CNS Disord* 2022; 24:22cr03237. 75. DeRemer CE, et al. Clozapine drug-induced pancreatitis of intermediate latency of onset confirmed by de-challenge and re-challenge. *Int J Clin Pharmacol Ther* 2019; 57:37–40. 76. Immadisetty V, et al. A successful treatment strategy for clozapine-induced parotid swelling: a clinical case and systematic review. *Ther Adv Psychopharmacol* 2012; 2:235–239. 77. Gouzien C, et al. [Clozapine-induced parotitis: a case study]. *Encephale* 2014; 40:81–85. 78. Saguem BN, et al. Eosinophilia and parotitis occurring early in clozapine treatment. *Int J Clin Pharm* 2015; 37:992–995. 79. Vohra A. Clozapine-induced recurrent and transient parotid gland swelling. *Afr J Psychiatry (Johannesbg)* 2013; 16:236, 238. 80. Kathirvel N, et al. Recurrent transient parotid gland swelling with clozapine therapy. *Ir J Psychol Med* 2014; 25:69–70. 81. Brodtkin ES, et al. Treatment of clozapine-induced parotid gland swelling. *Am J Psychiatry* 1996; 153:445. 82. Vasile JS, et al. Clozapine and the development of salivary gland swelling: a case study. *J Clin Psychiatry* 1995; 56:511–513. 83. Bhatti MA, et al. Clozapine-induced pericarditis, pericardial tamponade, polyserositis, and rash. *J Clin Psychiatry* 2005; 66:1490–1491. 84. Boot E, et al. Pericardial and bilateral pleural effusion associated with clozapine treatment. *Eur Psychiatry* 2004; 19:65. 85. Murko A, et al. Clozapine and pericarditis with pericardial effusion. *Am J Psychiatry* 2002; 159:494. 86. Imon Paul MD, et al. Clozapine induced pericarditis: an overlooked adverse effect. *Clin Schizophr Relat Psychoses* 2014; 8:133–134. 87. Bath AS, et al. Pericardial effusion: rare adverse effect of clozapine. *Cureus* 2019; 11:e4890.

Schizophrenia and related psychoses CHAPTER 1 88. Johal HK, et al. Clozapine-induced pericarditis: an ethical dilemma. *BMJ Case Rep* 2019; 12:e229872. 89. Sahyouni C, et al. Clozapine induced pericarditis: a case report. *Psychiatry Res* 2021; 305:114250. 90. Gilbreth N, et al. Clozapine--induced pericardial effusion presenting with persistent tachycardia. *Case Rep Med* 2021; 2021:5523562. 91. Prisco V, et al. Brain natriuretic peptide as a biomarker of asymptomatic clozapine-related heart dysfunction: a criterion for a more cautious administration. *Clin Schizophr Relat Psychoses* 2016; 12:185–188. 92. Crews MP, et al. Clozapine rechallenge following clozapine--induced pericarditis. *J Clin Psychiatry* 2010; 71:959–961. 93. Sarathy K, et al. A successful re-trial after clozapine myopericarditis. *J R Coll Physicians Edinb* 2017; 47:146–147. 94. Boscutti A, et al. Successful clozapine rechallenge after myopericarditis: a case report. *Int Clin Psychopharmacol* 2022; 37:179–181. 95. Nikvarz N, et al. Drug-induced stuttering: a comprehensive literature review. *World J Psychiatry* 2022; 12:236–263. 96. Trenque T, et al. Drug induced stuttering: pharmacovigilance data. *Expert Opin Drug Saf* 2021; 20:373–378. 97. Duggal HS, et al. Clozapine--induced stuttering and seizures. *Am J Psychiatry* 2002; 159:315. 98. Jagadheesan K, et al.

Clozapine-induced thrombocytopenia: a pilot study. *Hong Kong J Psychiatry* 2003; 13:12–15. 99. Mihaljevic-Peles A, et al. Thrombocytopenia associated with clozapine and fluphenazine. *Nord J Psychiatry* 2001; 55:449–450. 100. Rudolf J, et al. Clozapine-induced agranulocytosis and thrombopenia in a patient with dopaminergic psychosis. *J Neural Transm (Vienna)* 1997; 104:1305–1311. 101. Assion HJ, et al. Lymphocytopenia and thrombocytopenia during treatment with risperidone or clozapine. *Pharmacopsychiatry* 1996; 29:227–228. 102. Lee J, et al. The effect of clozapine on hematological indices: a 1-year follow-up study. *J Clin Psychopharmacol* 2015; 35:510–516. 103. Grover S, et al. Haematological side effects associated with clozapine: a retrospective study from India. *Asian J Psychiatr* 2020; 48:101906. 104. Kate N, et al. Clozapine associated thrombocytopenia. *J Pharmacol Pharmacother* 2013; 4:149–151. 105. Gonzales MF, et al. Evidence for immune etiology in clozapine-induced thrombocytopenia of 40 months' duration: a case report. *CNS Spectr* 2000; 5:17–18. 106. Hauseux PA, et al. Clozapine rechallenge after thrombocytopenia: a case report. *Schizophr Res* 2020; 222:477–479. 107. Thapaliya S, et al. Effective and safe use of intramuscular clozapine in a patient presenting with catatonia and thrombocytopenia. *BMJ Case Rep* 2024; 17:e260197. 108. Hampson ME. Clozapine-induced thrombocytosis. *Br J Psychiatry* 2000; 176:400. 109. Warnock JK, et al. Adverse cutaneous reactions to antipsychotics. *Am J Clin Dermatol* 2002; 3:629–636. 110. Wu BY, et al. Prevalence and associated factors of comorbid skin diseases in patients with schizophrenia: a clinical survey and national health database study. *Gen Hosp Psychiatry* 2014; 36:415–421. 111. Voulgari C, et al. Clozapine-induced late agranulocytosis and severe neutropenia complicated with streptococcus pneumonia, venous thromboembolism, and allergic vasculitis in treatment-resistant female psychosis. *Case Rep Med* 2015; 2015:703218. 112. Penaskovic K, et al. Clozapine-induced allergic vasculitis [Letter]. *Am J Psychiatry* 2005; 162:1543–1542. 113. Mukherjee S, et al. Leukocytoclastic vasculitis secondary to clozapine. *Indian J Psychiatry* 2019; 61:94–96. 114. Fujimoto S, et al. Clozapine-induced antineutrophil cytoplasmic antibody-associated vasculitis: a case report. *Mod Rheumatol Case Rep* 2020; 4:70–73. 115. Wu MK, et al. The severe complication of Stevens-Johnson syndrome induced by long-term clozapine treatment in a male schizophrenia patient: a case report. *Neuropsychiatr Dis Treat* 2015; 11:1039–1041. 116. Lai YW, et al. Pityriasis rosea-like eruption associated with clozapine: a case report. *Gen Hosp Psychiatry* 2012; 34:703.e5–e7. 117. Bhatia MS, et al. Clozapine induced pityriasiform eruption. *Indian J Dermatol* 1997; 42:245–246. 118. Stanislav SW, et al. Papular rash and bilateral pleural effusion associated with clozapine. *Ann Pharmacother* 1999; 33:1008–1009. 119. Bosonnet S, et al. [Acute generalized exanthematic pustulosis after intake of clozapine (leponex). First case]. *Ann Dermatol Venereol* 1997; 124:547–548. 120. El Ouni Amami N, et al. Clozapine-induced cholinergic urticaria: a case report. *Ther Adv Psychopharmacol* 2024; 14:20451253241241056. 121. Bunting A, et al. Clozapine and Sweet's syndrome: case report. *BJPsych Open* 2023; 9:e166. 122. Kleinen JM, et al. [Clozapine-induced agranulocytosis and Sweet's syndrome in a 74-year-old female patient: a case study]. *Tijdschr Psychiatr* 2008; 50:119–123. 123. de Filippis R, et al. Clozapine-related drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a systematic review. *Expert Rev Clin Pharmacol* 2020; 13:875–883. 124. Chate S, et al. Pulmonary thromboembolism associated with clozapine. *J Neuropsychiatry Clin Neurosci* 2013; 25:E3–E6. 125. Yang TY, et al. Massive pulmonary embolism in a young patient on clozapine therapy. *J Emerg Med* 2004; 27:27–29. 126. Huang J, et al. Association between antipsychotics and pulmonary embolism: a pharmacovigilance analysis. *Expert Opin Drug Saf* 2024; doi: 10.1080/14740338.2024.2396390. 127. Gami RK, et al. Pulmonary embolism and clozapine use: a case report and literature review. *Psychosomatics* 2017; 58:203–208. 128. Hagg S, et al. Risk of venous thromboembolism due to antipsychotic drug

therapy. Expert Opin Drug Saf 2009; 8:537–547. 129. De Fazio P, et al. Rare and very rare adverse effects of clozapine. Neuropsychiatr Dis Treat 2015; 11:1995–2003. 130. Sarvaiya N, et al. Clozapine-associated pulmonary embolism: a high-mortality, dose-independent and early-onset adverse effect. Am J Ther 2018; 25:e434–e438. 131. Pallares Vela E, et al. Clozapine-related thromboembolic events. Cureus 2021; 13:e16883. 132. Robbins-Welty GA, et al. Pulmonary embolism during a retrial of low-dose clozapine. Clin Psychopharmacol Neurosci 2022; 20:578–580.

250 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 133. Goh JG, et al. A case report of clozapine continuation after pulmonary embolism in the context of other risk factors for thromboembolism. Aust N Z J Psychiatry 2016; 50:1205–1206. 134. Munoli RN, et al. Clozapine--induced recurrent pulmonary thromboembolism. J Neuropsychiatry Clin Neurosci 2013; 25:E50–E51. 135. Selten JP, et al. Clozapine and venous thromboembolism: further evidence. J Clin Psychiatry 2003; 64:609. 136. Manoubi SA, et al. Fatal pulmonary embolism in patients on antipsychotics: case series, systematic review and meta-analysis. Asian J Psychiatr 2022; 73:103105. 137. Mouaffak F, et al. Clozapine-induced serositis: review of its clinical features, pathophysiology and management strategies. Clin Neuropharmacol 2009; 32:219–223. 138. Bonnet U, et al. Late-onset polyserositis emerging during long-term clozapine treatment and persisting after clozapine discontinuation: is clozapine really innocent? J Clin Psychopharmacol 2022; 42:106–107.

Revision #1

Created 2026-01-04 20:13:25 UTC by Omar Ayman

Updated 2026-01-04 20:13:25 UTC by Omar Ayman